Our capabilities
High-quality mRNA-LNPs
- End-to-end workflow, from sequence design to in vivo testing.
- Optimised manufacture for consistent, high-quality mRNA-LNPs.
- Rigorous quality analysis of every mRNA-LNP batch.
- Scalable production from small (µg) to large (mg+) batches.
Scientific expertise
- mRNA-LNPs validated across a wide range of applications.
- Strong, durable expression across diverse cell and tissue types.
- Practical experimental support, protocols, and expert advice.
- Access to partner UQ facilities for preclinical testing.
What we deliver
- Designed and optimised mRNA sequences.
- mRNA-LNP batches meeting rigorous quality specifications.
- Detailed QC reports for every batch.
- Dedicated experimental support and scientific guidance.
1. Sequence design
A great mRNA starts with a great design.
BASE scientists have developed a software toolkit, mRNArchitect, to design and optimise the primary sequence of mRNA medicines for better expression, stability, and immunogenicity.
Our validated library of mRNA elements, including UTRs, signal peptides, transmembrane domains, and localisation signals, can be incorporated into your design to further enhance performance.
Every mRNA sequence is delivered with a detailed QC report, full IP ownership and complete confidentiality.
2. mRNA synthesis
Our cell-free synthesis workflow delivers high-quality mRNA-LNPS, with accuracy, consistency, and reproducibility at every step.
Our DNA templates are prepared using a PCR-based method that incorporates a defined poly-A tail. The mRNA is then synthesised by in vitro transcription, with co-transcriptional 5′ capping and modified nucleotides to enhance expression and reduce immunogenicity.
mRNA synthesis is scalable, from small batches for pilot studies and candidate screening, to large-scale production suitable for pre-clinical and in vivo testing.
3. LNP formulation
mRNA medicines are formulated within LNPs for efficient delivery to target cells and tissues.
BASE scientists have produced hundreds of mRNA-LNPs, with experience in formulation, purification, and particle characterisation. We work with a broad range of lipid compositions, mRNA cargoes, and excipients, including novel and custom lipid, to develop formulations tailored to your application.
We also support both passive and active (conjugated) approaches to target mRNA-LNPs to specific cell types and tissues.
4. Quality control
The quality of mRNA-LNPs is critical for performance.
Each batch undergoes rigorous quality control, with comprehensive testing to confirm mRNA identity, integrity, and purity, as well as LNP particle size, uniformity, and encapsulation efficiency. Every batch is accompanied by a detailed QC report accompanies to ensure it meets quality specifications.
For in vivo applications, we also test batches for key impurities, including endotoxin and dsRNA, with nanopore sequencing available for direct, single-molecule characterisation of mRNA accuracy and integrity.
5. mRNA-LNP testing
BASE scientists can evaluate mRNA-LNP performance using both in vitro and in vivo assays, including potency and stability testing. These research service can help accelerate the development of your mRNA-LNP medicines.
Through our partner laboratories at The University of Queensland, we also offer pre-clinical services including safety, toxicity, biodistribution, and stability analysis.
Specifications
Shipping
Dispatched in 1–2 days
Scale
100 µg to 10+ mg
Design
Design
mRNArchitect (max CAI, min MFE)
UTRs
human beta-globin
Poly(A) tail
126nt
Production
Nucleotides
m1Ψ
5′ cap
Co-transcriptional Cap-1
DNA template
PCR (cell-free)
mRNA synthesis
IVT using T7 polymerase
mRNA purification
oligo(dT)
LNPs
Standard
Quality control
mRNA yield
UV
mRNA integrity
Capillary Gel Electrophoresis
Additional purity
dsRNA, endotoxin
LNP quality
DLS, encapsulation
Production facilities
BASE has established a purpose-built, high-throughput production facility to manufacture small-scale (µg) mRNA-LNP batches for discovery experiments, to large (g) scale batch for translational programs.
The production facility is supported by a dedicated bioinformatics design team, segregated production suites, and adjacent quality control laboratories to ensure reliable and reproducible manufacture of high-quality mRNA–LNP medicines.
Located at the Translational Research Institute (TRI)m within the Boggo Road Innovation Precinct, the facility places BASE at the heart of Queensland’s translational research ecosystem, enabling close collaboration with academic, clinical, and industry partners.
BASE Manufacture Facility
Level 6, Translational Research Institute37 Kent St
Woolloongabba, QLD 4102, AU
Enquiries
Our team is available to help with your mRNA projects.